ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi has laid out a five-year plan that targets a reduction of $1.6 billion in operating costs as well as annual sales growth of 3 to 4%. The firm warns, however, that it will not see any significant bottom-line growth for the next two years given the phasing of cost savings and “headwinds” in the diabetes market. The company says it is considering selling its Merial animal health business and its European generics businesses. The company says growth will be driven by launches scheduled through 2020, with six key launches, including diabetes and high cholesterol treatments and a vaccine for dengue fever, together expected to generate sales of up to $15 billion by 2025.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter